NO EFFECT ON THE SAFETY & EFFICACY OF ORAL CONTRACEPTIVES. NO CLINICALLY SIGNIFICANT DRUG INTERACTIONS NOTED WITH DIGOXIN, METOPROLOL, RIFAMPICIN ETC.
DRUGS THAT INHIBIT CYP2D6 AND CYP3A PATHWAYS MAY SIGNIFICANTLY INCREASE THE EXPOSURE TO ELIGLUSTAT AND RESULT IN PROLONGATION OF THE PR, QTC, AND/OR QRS CARDIAC INTERVAL WHICH COULD RESULT IN CARDIAC ARRHYTHMIAS.